Kamada Ltd. (NASDAQ:KMDA)’s share price gapped up prior to trading on Friday . The stock had previously closed at $4.18, but opened at $4.20. Kamada shares last traded at $4.30, with a volume of 11,300 shares changing hands.

A number of equities analysts have recently weighed in on KMDA shares. Zacks Investment Research upgraded Kamada from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Thursday, August 4th. TheStreet downgraded Kamada from a “hold” rating to a “sell” rating in a report on Thursday, June 9th.

The company has a 50-day moving average price of $3.96 and a 200-day moving average price of $3.84. The stock’s market cap is $154.78 million.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The firm earned $19.10 million during the quarter, compared to analyst estimates of $18.50 million. Analysts expect that Kamada Ltd. will post ($0.11) EPS for the current fiscal year.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.